Prediction of sarcopenia using a battery of circulating biomarkers

Rizwan Qaisar1,*, Asima Karim1,2, Tahir Muhammad3, Islam Shah4 & Javaidullah Khan5

Loss of muscle mass and strength with aging, termed sarcopenia is accelerated in several comorbidities including chronic heart failure (CHF) and chronic obstructive pulmonary diseases (COPD). However, the effective circulating biomarkers to accurately diagnose and assess sarcopenia are not known. We recruited male healthy controls and patients with CHF and COPD (n = 81–87/group), aged 55–74 years. Sarcopenia was clinically identified based on hand-grip strength, appendicular skeletal muscle index and physical capacity as recommended by the European working group for sarcopenia. The serum levels of amino-terminal pro-peptide of type-III procollagen, c-terminal agrin fragment-22, osteonectin, irisin, fatty acid-binding protein-3 and macrophage migration inhibitory factor were significantly different between healthy controls and patients with CHF and COPD. Risk scores for individual biomarkers were calculated by logistic regressions and combined into a cumulative risk score. The median cutoff value of 3.86 was used to divide subjects into high- and low-risk groups for sarcopenia with the area under the curve of 0.793 (95% CI = 0.738–0.845, \( p < 0.001 \)). A significantly higher incidence of clinical sarcopenia was found in high-risk group. Taken together, the battery of biomarkers can be an effective tool in the early diagnosis and assessment of sarcopenia.

Sarcopenia is traditionally defined as the loss of muscle mass with aging1. However, recent definitions of sarcopenia consider the loss of muscle mass, strength and physical capacity with aging2. For example, the European Working Group for Sarcopenia (EWGSOP) defines sarcopenia as muscle atrophy (normalized for height) combined with muscle weakness (measured in hand-grip muscles) and/or reduced physical capacity (measured via gait speed)3. Among these parameters, muscle weakness has emerged as the primary determinant of sarcopenia and functional dependency in aging2. Elderly with low muscle mass (normalized for height) in the absence of muscle weakness and functional compromise are categorized in "pre-sarcopenia" phase, while "probable sarcopenia" is defined as reduced hand-grip strength (HGS) and/or compromised physical capacity (low chair stand test ability)4, which warrants further assessments. These assessments highlight the importance of sarcopenia as the muscle impairment in the elderly is often associated with a dependent lifestyle due to physical decline5, falls5, fractures5 and increased morbidities6.

Several methods are used to assess the indexes of sarcopenia. MRI and CT scans are considered the gold standards to measure muscle mass but are costly, require technical expertise and involve radiation exposure. Bioelectrical impedance is now widely implied due to its simple and cost-effective manner despite less reliability due to gender, ethnicity and hydration status7. Muscle strength is routinely measured in the hand-grip muscles with a dynamometer and shows a correlation with several age-related diseases8–10. Additionally, a short physical performance battery (SPPB) has emerged as a promising tool to evaluate functional capacity and incorporates standing balance and chair stand test in addition to gait speed11. SPPB has shown high sensitivity for sarcopenia and maybe a favorable tool in clinical settings as it is a simple and quick test, which does not require any specialized instruments.

In addition to clinical measurements, sarcopenia is also definable by simple functional questions. SARC-F questionnaire has emerged as a useful tool for the rapid assessment of sarcopenia12. It considers various measures of functional independence such as strength, assistance in walking, rising from a chair, climbing stairs and falls. Each component is awarded a score from 0 to 10, with a maximal score of 10 in the overall assessment. A score ≥ 4 is considered as a predictor of sarcopenia12.

Several co-morbidities can induce and/or exacerbate the sarcopenia phenotype in aging. These diseases also share several common risk factors and health outcomes with sarcopenia. However, sarcopenia is frequently underdiagnosed in clinical practice despite the considerable overlap in the severities of sarcopenia phenotype and

---

1Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. 2University of Health Sciences, Lahore, Pakistan. 3Department of Biochemistry, Gomal Medical College, Dera Ismail Khan, Pakistan. 4Department of Cardiology, Al Qassimi Hospital, Sharjah, United Arab Emirates. 5Department of Cardiology, Post Graduate Medical Institute, Hayatabad Medical Complex, Peshawar, Pakistan. *email: rqaisar@sharjah.ac.ae
comorbidities. Further, treatment protocols for sarcopenia do not take comorbidities into account\(^1\). Therefore, there is a need to determine the diagnosis and prevalence of sarcopenia in the elderly with age-related comorbidities. Among them, chronic obstructive pulmonary diseases (COPD) and congestive heart failure (CHF) are common drivers of sarcopenia in the elderly\(^1\). We have previously shown that patients with respiratory diseases have accelerated loss of muscle mass and strength than the age-matched healthy elderly\(^9\).

Several molecular mechanisms contribute to the pathogenesis of sarcopenia. Both the intrinsic (generalized inflammation, oxidative stress, calcium dysregulation, apoptosis, hypoxia, the disintegration of neuromuscular junction) and extrinsic (chronic inactivity, poor nutrition, endocrine dysfunction) factors contribute to the loss of muscle mass and strength in aging\(^1\). However, considering the complex pathophysiology, no single molecular biomarker can accurately evaluate the sarcopenia phenotype, necessitating the use of multiple biomarkers to assess loss of muscle mass and strength in the elderly.

Given the complexity of sarcopenia, we tested a battery of circulating biomarkers as a strategy to define a biomarker panel specific to different pathophysiological mechanisms of sarcopenia. We evaluated specific biomarkers to assess the neuromuscular junction integrity (c-terminal agrin fragment 22 or CAF22), protein turnaround (amino-terminal pro-peptide of type III procollagen or P3NP), cell–matrix interaction (osteonectin), growth factors (irisin), cellular metabolism (fatty acid-binding protein 3 or FABP3) and systemic inflammation (macrophage migration inhibitory factor or MIF). The circulating biomarker levels were correlated with the sarcopenia as defined by clinical parameters or SARC-F questionnaire to assess their diagnostic significance. The comparative analysis of the biomarkers was performed in the normal elderly with sarcopenia and the patients of COPD and CHF with advanced sarcopenia.

### Results

#### Characteristics of the participants.

The basic characteristics of the study population are summarized in Table 1.

|                  | Healthy | COPD   | CHF    |
|------------------|---------|--------|--------|
| Age at baseline (years) | 62.6 ± 5.5 | 64.3 ± 3.7 | 66.9 ± 5.4 |
| Body composition |
| BMI (Kg/m\(^2\))   | 23.85 ± 2.76 | 22.27 ± 3.25 | 25.62 ± 3.32*# |
| ASM (Kg)           | 20.29 ± 3.08 | 19.27 ± 2.61 | 19.41 ± 3.24 |
| ASMI (Kg/m\(^2\))  | 7.24 ± 1.45  | 7.03 ± 1.38* | 6.84 ± 1.44* |
| Percent fat        | 27.79 ± 3.15 | 25.18 ± 3.85* | 28.43 ± 3.63* |
| Physical parameters |
| HGS (kg)           | 25.57 ± 5.36 | 20.19 ± 4.37* | 21.45 ± 3.31* |
| HGS / ASMI         | 1.26 ± 0.18  | 1.04 ± 0.14* | 1.01 ± 0.17* |
| Daily steps count  | 6873 ± 1394  | 3182 ± 949*  | 3648 ± 1203* |
| 4-meter gait speed (m/s) | 1.23 ± 0.21   | 0.87 ± 0.18* | 0.83 ± 0.17* |
| Chair stand for five rises (s) | 13.5 ± 2.54    | 15.4 ± 3.11  | 16.7 ± 3.69* |

|                  | Healthy | COPD   | CHF    |
|------------------|---------|--------|--------|
| Spirometry and oxygen saturation |
| FEV1% predicted  | 97.39 ± 3.3 | 61.89 ± 5.7* | 66.31 ± 4.3*# |
| PEFR % predicted | 93.53 ± 4.7 | 67.39 ± 4.5* | 73.61 ± 4.1* |
| SpO\(_2\)        | 98.5 ± 1.5  | 95.3 ± 2.2  | 95.1 ± 2.4  |
| Plasma biomarkers |
| Plasma 8-isoprostanes (pg/ml) | 58.4 ± 12.7 | 95.2 ± 16.9* | 87.9 ± 13.4* |
| CRP (mg/l)       | 1.91 ± 0.24 | 3.26 ± 0.43* | 3.53 ± 0.47*# |
| Creatine kinase (IU/L) | 167.9 ± 25.7 | 293.5 ± 52.7* | 279.9 ± 42.9* |

Table 1. Body composition, physical parameters and circulating biomarkers in healthy controls and patients with COPD and CHF. Values are expressed as mean ± SD, one-way analysis of variance. *p < 0.05 vs. healthy controls; #p < 0.05 vs. COPD participants; (N = 83–88/group). (BMI; body mass index, ASM; appendicular skeletal mass, ASMI; appendicular skeletal mass index, HGS; hand-grip strength, FEV1; forced expiratory volume in 1 s, PEFR; peak expiratory flow rate, CRP; C—reactive protein).
patients with normal and advanced phases of sarcopenia. Among various candidates investigated, circulating biomarkers for sarcopenia were selected based on the relevant literature and our previous investigations in Correlation of biomarkers with functional capacity and sarcopenia indexes.

Significance of the biomarkers panel in accurate diagnosis of sarcopenia.

Application of predictive probabilities of sarcopenia using combinations of biomarkers.

Circulating biomarkers accurately identify advanced sarcopenia in COPD and CHF.

Since individual biomarkers often lack in specificity and/or sensitivity in the assessment of sarcopenia than the panels of biomarkers, we next integrated the measurements of several biomarkers to enhance the diagnostic potential of sarcopenia. We first generated predicted probabilities of sarcopenia using logistic regression coefficients of individual biomarkers. We then added the predicted probabilities of all biomarkers to generate risk scores for each individual participant. All participants were divided into the high-risk and low-risk groups based on the median cut-off value of 3.86 (Fig. 4A). We found a significantly higher proportion of sarcopenia patients (based on EWGSOP criteria) in the high-risk than low-risk groups (p < 0.05; 95% CI of diff. − 30.11 to − 10.20) (Fig. 4D) indicating the usefulness of the biomarker panel in predicting sarcopenia associated with age-related diseases (Fig. 5C,D). Taken together, these results suggest that the panel of multiple biomarkers can be a useful tool to predict varying degrees of sarcopenia in the healthy and diseased elderly participants.

Significance of the biomarkers panel in accurate diagnosis of sarcopenia.

Correlation of biomarkers with functional capacity and sarcopenia indexes.
HGS and the gait speed (Table 2). Among the individual biomarkers, CAF22 showed the strongest correlation with ASMI ($r^2 = 0.315$, $p < 0.001$) followed by osteonectin ($r^2 = 0.278$, $p < 0.001$) and irisin ($r^2 = 0.263$, $p < 0.001$) in all subjects. HGS was significantly correlated with all six biomarkers, and the strongest correlation was found with irisin ($r^2 = 0.475$, $p < 0.001$). Association of gait speed with the levels of biomarkers was less robust and was the strongest with osteonectin ($r^2 = 0.236$, $p < 0.001$). Generally, we found stronger associations between biomarkers levels and the sarcopenia indexes in the COPD and CHF groups than the healthy controls. Irisin and osteonectin emerged as the useful biomarkers to predict sarcopenia indexes in COPD and CHF patients, while the other biomarkers showed varying degrees of correlations with sarcopenia indexes (Table 2).

Correlation of circulating biomarkers with markers of inflammation, oxidative stress and muscle damage. Since the inflammation, oxidative stress and muscle structural integrity can affect the sarcopenia status, we next evaluated the correlations of the plasma 8-isoprostanes, CRP and CK levels with the selected panel of biomarkers. Plasma 8-isoprostanes levels, a marker of oxidative stress showed a significant correlation with all the selected biomarkers, with irisin ($r^2 = 0.293$), MIF ($r^2 = 0.275$) and osteonectin ($r^2 = 0.271$) showing the strongest correlation (Table 3). Plasma CRP level, a marker of generalized inflammation showed a significant correlation with all the selected biomarkers when all subjects were pooled together. The strongest correlation was found with plasma irisin ($r^2 = 0.249$) and FABP3 ($r^2 = 0.201$) levels (Table 3). Circulating CK levels are a marker of muscle damage and showed the strongest correlations with CAF22 ($r^2 = 0.229$) and osteonectin ($r^2 = 0.219$) among the selected panel of biomarkers. In all analysis, the values of correlation coefficients were slightly higher in the patients with COPD and CHF, when compared to healthy controls (Table 3).
Since inflammation and oxidative stress can contribute to loss of muscle mass and strength in aging\textsuperscript{20}, we next measured the circulating markers of inflammation and oxidative stress. We found higher mRNA levels of pro-inflammatory cytokines interleukin-10 (IL-10), transforming growth factor-beta 1 (TGF-\(\beta\)1), C–C motif chemokine receptor 5 (CCR5), (interleukin-8) IL-8 and adrenomedullin (ADM) in patients with COPD and CHF (all \(p<0.05\)), indicating increased inflammation in these diseases (supplementary Fig. 1). Additionally, plasma levels of chemokine ligand 2 (CXCL2) were higher in CHF patients. Among the markers of oxidative stress, we found higher expressions of superoxide dismutase 1 (SOD1), catalase, glutathione synthetase (GSS) and glutathione peroxidase 1 (GPX1) in both disease groups than healthy controls (all \(p<0.05\)), indicating increased oxidative stress (supplementary Fig. 1).

**Discussion**

We investigated the diagnostic potential of six circulating biomarkers related to distinct pathophysiological mechanisms of sarcopenia. Healthy controls and the patients with comorbidities were selected to obtain a wide range of sarcopenia phenotypes from early to advanced stages. A significantly higher incidence of sarcopenia was found in patients with COPD and CHF compared to healthy controls. While the candidate biomarkers were useful in the identification of sarcopenia, the combination of biomarkers enhanced the diagnostic accuracy of sarcopenia in the elderly.

There has been an increasing emphasis to identify the biomarkers of sarcopenia. However, most studies mainly focus on muscle mass and/or strength with relatively little emphasis on the functional capacity in the elderly. Considering that the EWGSOP2 recently updated its definition of sarcopenia\textsuperscript{a}, our study better contributes...
to the biomarker assessment of sarcopenia by evaluating SPPB in the elderly. Additionally, the incorporation of the SARC-F questionnaire in biomarkers evaluation can be useful in assessing early asymptomatic cases of sarcopenia. Given the multifactorial nature of sarcopenia, we selected biomarkers that are evidently correlated with skeletal muscle metabolism, growth, regeneration, and systemic inflammation.

The detonation of the neuromuscular junction (NMJ) is one of the hallmarks of sarcopenia. Agrin is a major protein maintaining NMJ integrity by aggregating the acetylcholine receptors at the post-synaptic terminal. Sarcopenia and other catabolic conditions disrupt NMJ integrity via proteolytic cleavage of agrin into CAF22 that can be detected in circulation. We have previously shown that plasma CAF22 levels are increased in sarcopenia with pulmonary diseases. Here, we confirm and extend these findings to sarcopenia with CHF. Patients with accelerated sarcopenia consistently showed higher serum CAF22 levels than the healthy controls. However, the serum CAF22 levels were not correlated with the SPPB and SARC-F scores in individual cohorts of participants.

P3NP is a fragment of procollagen III and is released into the circulation during the final stages of collagen synthesis. Higher circulating P3NP levels have been observed in degenerating conditions with generalized chronic inflammation and fibrosis. An association between plasma P3NP and changes in lean muscle mass has been observed in hormonal therapies and exercise training. Higher plasma P3NP levels have also been observed in sarcopenia, although the effect was more pronounced in women. We report an additional increase in P3NP levels in advanced sarcopenia, eliciting the role(s) of increased chronic inflammation and fibrosis in COPD and CHF.

Osteonectin is a glycoprotein in the extracellular matrix and is involved in cell–matrix interaction. Over-expression of osteonectin inhibits differentiation of C2C12 muscle cells. Accordingly, patients with myopathies show increased expressions of osteonectin. There is also a correlation with aging as reduced muscle mass in sarcopenia is inversely related to the circulating osteonectin levels. Our finding of higher osteonectin levels in age-associated comorbidities confirms and extends the usefulness of osteonectin as a biomarker of sarcopenia. Irsin is a pro-myogenic factor and its serum expression increases following exercise. Circulating irisin levels correlate well with biceps circumference and are also increased in mice with increased muscle mass due to myostatin deficiency. Low circulating irisin levels in the elderly have emerged as a sensitive marker of muscle mass and strength in sarcopenia. We report that the irisin concentration is further reduced in sarcopenia patients with COPD and CHF, eliciting its negative correlation with muscle mass and strength in the elderly. Importantly, exercise restores irisin levels and protects against muscle loss and lung dysfunction in COPD.

FABP3 is highly expressed in skeletal muscle and works as a lipid chaperon, as consumption of high-fat diet increases its muscle expression. FABP3 expression also increases in sarcopenic muscle and contributes to muscle atrophy and weakness by inducing endoplasmic reticulum stress. We found higher levels of circulating FABP3 in the patient with COPD and CHF, which integrate with the contribution(s) of ER stress to skeletal muscle remodeling in COPD and CHF.

Figure 4. Cumulative risk score for all the participants based on six biomarkers (P3NP, CAF22, osteonectin, irisin, FABP3 and MIF). The scatter plot of the participants with the median risk score (cutoff value = 3.86) was applied to divide into high- and low-risk groups (A). The relative proportion of the clinically diagnosed sarcopenic patients in the two risk-groups (B) and participants’ categorization based on SARC-F scores (C) in the three study cohorts. The relative proportion of the sarcopenic patients as defined by SARC-F criteria in the two risk-groups (D) in healthy controls and patients with COPD and CHF. *p < 0.05.
MIF is a pro-inflammatory cytokine with implications in skeletal muscle atrophy and weakness in inflammatory myopathies. Since sarcopenia is associated with high inflammation, we speculated that the circulating MIF levels may reflect the skeletal muscle weakness and atrophy in the elderly with varying degrees of sarcopenia. Accordingly, patients with COPD and CHF who had higher inflammatory cytokines and advanced sarcopenia, also expressed higher circulating levels of MIF.

Sarcopenia group in our cohorts include the elderly with reduced muscle mass, strength, and physical capacity. According to the revised definition by EWGSOP, low muscle strength has emerged as a key determinant of sarcopenia, while reduced muscle quantity is used for confirmation of sarcopenia. These parameters along with reduced physical capacity determine the functional dependency in the elderly. Due to a lack of established circulating biomarkers of sarcopenia, our choice of biomarkers was based on our previous investigations and the published literature. The median cut-off was selected empirically to generate useful high- and low-risk groups. A significantly higher proportion of sarcopenic patients in the high-risk group shows the predictive accuracy of the biomarkers panel. Additionally, we show that the SARC-F questionnaire has acceptable diagnostic value and can be used as a fast and early assessment tool in sarcopenia.

From a practical standpoint, the battery of biomarkers can be useful in the screening of sarcopenia. These assays require ≤1 ml of plasma, which can be obtained from the blood drawn for other investigations. This ensures the screening without the need for additional blood sampling. Measurement and analysis of biomarkers can be performed in additional few hours to evaluate the diagnosis and/or risk probability of sarcopenia for each subject.

This study only incorporated male participants, so the inclusion of female participants to understand complex etiology of sarcopenia and the contribution of menopause to muscle loss may be required. Considering the multifactorial nature of sarcopenia, the evaluation of six biomarkers may not encompass the several molecular

![Figure 5](image-url)

**Figure 5.** Significance of cumulative risk score for all the participants based on six biomarkers (P3NP, CAF22, osteonectin, irisin, FABP3 and MIF). Receiver operating characteristic (ROC) curves for all the participants (A), healthy controls (B) and the patients with COPD (C) and CHF (D). The area under the curve (AUC) was calculated for each group to determine the significance of the biomarkers panel in diagnosis of sarcopenia.
mechanisms dictating sarcopenia phenotype in the elderly. Thus, the use of additional biomarkers and optimizing the combinations of biomarkers is required to reflect the entire biological changes dictating skeletal muscle impairment in sarcopenia. Additionally, longitudinal studies are essential to evaluate the diagnostic and prognostic potential of biomarkers during therapeutic interventions. Since inflammation and oxidative stress are hallmarks of several aging-related diseases, muscle-specific biomarkers with minimal interference by other diseases is required to assess sarcopenia.

**Table 2.** Correlations coefficients of circulating biomarkers with indexes of sarcopenia including ASMI, HGS and gait speed in healthy controls and patients with COPD and CHF (N = 83–87 per group). *p < 0.05, **p < 0.001. (P3NP; amino-terminal of type III pro-collagen peptide, CAF22; C-terminal Agrin fragment-22, FABP3; fatty acid-binding protein 3, MIF; Macrophage migration inhibitory factor).

| Biomarker | All subjects | Healthy controls | COPD | CHF |
|-----------|-------------|-----------------|------|-----|
| P3NP |  | | | |
| ASMI | −0.235** | −0.115* | −0.099* | −0.126* |
| HGS | −0.197** | −0.071 | −0.168* | −0.081 |
| Gait speed | −0.134* | −0.094* | −0.083 | −0.087 |
| CAF22 |  | | | |
| ASMI | −0.315** | −0.117* | −0.212** | −0.246** |
| HGS | −0.273** | −0.149* | −0.184* | −0.237* |
| Gait speed | −0.192* | −0.103* | −0.138* | −0.127* |
| Osteonectin |  | | | |
| ASMI | −0.278** | −0.132* | −0.179* | −0.365** |
| HGS | −0.351** | −0.101* | −0.296* | −0.318** |
| Gait speed | −0.236** | −0.153* | −0.142* | −0.184* |
| Irisin |  | | | |
| ASMI | 0.263** | 0.166* | 0.173* | 0.218** |
| HGS | 0.475** | 0.259* | 0.336* | 0.506** |
| Gait speed | 0.223** | 0.132* | 0.297** | 0.104* |
| FABP3 |  | | | |
| ASMI | −0.173* | −0.048 | −0.128* | −0.111* |
| HGS | −0.241** | −0.177* | −0.238** | −0.126** |
| Gait speed | −0.216** | −0.073 | −0.165* | −0.195** |
| MIF |  | | | |
| ASMI | −0.154* | −0.123* | −0.085* | −0.116* |
| HGS | −0.352** | −0.209** | −0.321** | −0.273** |
| Gait speed | −0.247** | −0.168* | −0.173* | −0.208** |

**Table 3.** Correlations coefficients of circulating biomarkers with plasma 8-isoprostanes, CRP and creatine kinase levels in healthy controls and patients with COPD and CHF (N = 83–87 per group). *p < 0.05, **p < 0.001. (P3NP; amino-terminal of type III pro-collagen peptide, CAF22; C-terminal Agrin fragment-22, FABP3; fatty acid-binding protein 3, MIF; Macrophage migration inhibitory factor).

| Biomarker | All subjects | Healthy controls | COPD | CHF |
|-----------|-------------|-----------------|------|-----|
| P3NP |  | | | |
| 8-isoprostanes | 0.125* | 0.085 | 0.058 | 0.082 |
| Plasma CRP | 0.119* | 0.127* | 0.095 | 0.103 |
| Creatine kinase | 0.125* | 0.075 | 0.091 | 0.124* |
| CAF22 |  | | | |
| 8-isoprostanes | 0.136* | 0.086 | 0.105 | 0.128 |
| Plasma CRP | 0.157* | 0.107 | 0.139* | 0.121* |
| Creatine kinase | 0.229** | 0.136* | 0.213** | 0.286** |
| Osteonectin |  | | | |
| 8-isoprostanes | 0.271** | 0.131* | 0.181* | 0.228** |
| Plasma CRP | 0.197** | 0.126* | 0.149* | 0.188** |
| Creatine kinase | 0.219** | 0.149* | 0.137* | 0.178* |
| Irisin |  | | | |
| 8-isoprostanes | −0.293** | −0.195** | −0.238** | −0.229** |
| Plasma CRP | −0.249** | −0.157* | −0.169* | −0.209** |
| Creatine kinase | −0.157* | −0.081 | −0.106* | −0.117* |
| FABP3 |  | | | |
| 8-isoprostanes | 0.213** | 0.193* | 0.183* | 0.208* |
| Plasma CRP | 0.201** | 0.127* | 0.135* | 0.174** |
| Creatine kinase | 0.166* | 0.143* | 0.179* | 0.149* |
| MIF |  | | | |
| 8-isoprostanes | 0.275** | 0.217** | 0.241** | 0.193** |
| Plasma CRP | 0.173* | 0.143* | 0.151* | 0.126* |
| Creatine kinase | 0.193* | 0.154* | 0.166* | 0.182** |
Methods
Study design and participants. We recruited 258 ambulatory participants as healthy controls (N = 87) and patients with COPD (N = 86) and CHF (N = 81) at the University of Health Sciences (UHS), Lahore, teaching hospital of Gomal Medical College (GMC), Dera Ismail Khan and cardiac rehabilitation center, Hayatabad Medical Complex (HMC), Peshawar, Pakistan. The healthy controls and COPD participants were taken from a large cohort of patients described elsewhere. The ethical review committee at the UHS, Institutional ethics committee at GMC and the clinical ethics committee at the HMC approved this study. All participants were male, 55–74 years old and provided written informed consent. COPD was defined as FEV1/forced vital capacity (FVC) < 0.7 with persistent respiratory symptoms according to the GOLD guidelines. The inclusion criteria for chronic HF patients were a diagnosis of heart failure with left ventricular ejection fraction ≤ 40%. Subjects with stable phenotype were included while those with the unstable phenotype (infection, exacerbation and/or hospitalization in the past month), arthritis, myopathies, neurological diseases, unstable angina, major surgeries and prolonged bed rest within eight weeks of the visit to the clinics were excluded. Subjects with higher plasma urea and/or creatinine were also excluded due to an independent association between plasma CAF22 levels and kidney function. Hence, our study protocol is consistent with previous studies used to characterize muscle wasting in patients with COPD and CHF. Based on the definition by the European Working Group on Sarcopenia in Older People (EWGSOP), sarcopenia was defined as low muscle strength (HGS < 27 kg), low muscle mass (ASM < 7 kg/m²) and low physical performance (SPPB ≤ 8 and/or gait speed ≤ 8 m/s). Data was collected from structural interviews, clinical examinations, laboratory investigations and measurements of physical parameters. SARC-F questionnaire was used as an independent and rapid diagnostic tool for sarcopenia. The questionnaire investigates various measures of physical performance as each measure given a score from 0 to 2 with a maximal score of 10. A score ≥ 4 was taken as a predictor of sarcopenia. This study was conducted in accordance with the declaration of Helsinki.

HGS and body composition. HGS was measured by a digital handgrip dynamometer (CAMRY, South El Monte, CA, USA) as described before. The participants were instructed to sit down with their elbows flexed at an angle of 90° with the dynamometer in hand in the supine position. The participants were then asked to squeeze the dynamometer with maximal strength in a smooth manner without rapid jerking or wrenching. No other body movement was allowed during the procedure. Three attempts were performed with each hand with 60-s rest between each attempt and the highest value was recorded for the analysis. Appendicular skeletal muscle mass (ASM) and fat mass were calculated with the bioelectrical impedance analysis scale (RENPHO, Dubai, UAE). ASM was divided by body area to get appendicular skeletal muscle mass index (ASMI), as described previously.

Measurement of physical performance. The physical performance was assessed by the SPPB score. This battery is composed of three timed tests: 4-m walking speed, balance, and chair-stand tests. Timed results from each test were rescored from zero (worst performers) to four (best performers). The sum of the results from the three categorized tests (ranging from 0 to 12) was used for the present analyses, as described elsewhere.

The walking speed was evaluated by measuring the participant's usual gait-speed (in m/s) over a 4-m course (4-m walk test; 4MWT). Based on the sample population quartiles, the following cut-points were used to categorize the gait speed: ≤ 0.38 m/s, a score of 1; 0.39–0.57 m/s, a score of 2; 0.58–0.76 m/s, a score of 3; ≥ 0.77 m/s, a score of 4.

To assess the chair-stand test, the participants were asked to stand up from a chair with their arms folded across the chest five times in a row as quickly as possible. The time needed to complete the task was recorded. The quartiles for the length of the time required for this measure were used for scoring as follows: ≥ 17.0 s, a score of 1; 14.1–16.9 s, a score of 2; 11.9–14.0 s, a score of 3; and ≤ 11.8 s, a score of 4.

To assess the balance test, the participants were asked to perform three increasingly challenging standing-positions: side-by-side position, semi-tandem position, and tandem position. Participants were asked to hold each position for 10 s. Participants were scored as 1 if they were able to hold a side-by-side standing position for 10 s, but were unable to hold a tandem position for more than 2 s; a score of 2; a score of 3 if they were able to stand in tandem position for 3–9 s; and a score of 4 if they were able to hold the tandem position for 10 s. Cut-off point for sarcopenia on SPPB score was taken as ≤ 8.

Measurement of circulating biomarkers. For analysis of circulating biomarkers, plasma samples were assayed using ELISA kits for P3NP (Cat # MBS9141338, MyBioSource, San Diego, USA), CAF22 (NTCAE, ELISA, Neutrotune, Schliren-Zurich, Switzerland), osteonectin (Cat # ab220654, Abcam, Abu Dhabi, UAE), irisin (Cat # MBS2600406, MyBioSource, San Diego, USA), FABP3 (Cat # ab243682, Abcam, Abu Dhabi, UAE) and MIF (Cat # ab100594, Abcam, Abu Dhabi, UAE) according to the manufacturer’s instructions.

Measurements of plasma 8-isoprostanes, CRP and creatine kinase. We used ELISA to measure 8-isoprostanes (Cayman Chemical, Ann Arbor, MI, USA) and CRP (R&D Systems, Minneapolis, MN, USA) levels and biochemical assays to measure creatine kinase levels, as described previously.

Quantification of RNA using real-time-PCR. Total RNA was extracted from the plasma using TRIzol reagent and the cDNA was prepared from 1 mg of the total RNA using a CDNA Synthesis kit (Bio-Rad, Hercules, CA, USA) as described previously. 2.5 ng of cDNA samples were amplified using specific primers along with
fast SYBR green master mix (Applied Biosystems, Grand Island, NY, USA). GAPDH rRNA was used as internal control. The data were analyzed using the ΔΔCT method.

**Spirometry and pulse oximetry.** The FEV1 and FVC were measured using a portable spirometer (Contec SP10, China), according to standards set by the American Thoracic Society.72 A commercially available pulse oximeter was used to measure SpO2, in healthy controls and patients with respiratory diseases (Nellcor N-200, Hayward, California).

**Statistical analysis.** Anthropometric measurements of the participants were presented using mean and standard deviation as data met the assumption for normality. Analysis of variance was used to compare groups and Pearson correlation was employed to determine the strength of the relationship between individual cohorts and various physical and biochemical parameters. Simple logistic regression analysis was used to calculate the predicted probability scores for each circulating biomarker. The areas under curve (AUC) were calculated using receiver operating characteristics (ROC) analysis to test the utility of risk scores. Two-sample t-test for percent was used to compare SPPB and SARC-F scores among the groups. A p value < 0.05 was statistically significant.

Received: 6 January 2021; Accepted: 6 April 2021
Published online: 21 April 2021

**References**

1. Cripte, A. et al. Effects of aging and gender on the spatial organization of nuclei in single human skeletal muscle cells. *Aging Cell* 9(5), 685–697 (2010).
2. Cruz-Jentoft, A. J. et al. Sarcopenia: Revised European consensus on definition and diagnosis. *Age Aging* 48(4), 601 (2019).
3. Cruz-Jentoft, A. J. et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Aging* 39(4), 412–423 (2010).
4. Beaudart, C. et al. Health outcomes of sarcopenia: A systematic review and meta-analysis. *PloS ONE* 12(1), e0169584 (2017).
5. Yeung, S. S. Y. et al. Sarcopenia and its association with falls and fractures in older adults: A systematic review and meta-analysis. *J. Cachexia Sarcopenia Muscle* 10(3), 485–500 (2019).
6. Baggerman, M. R. et al. Muscle wasting associated co-morbidities, rather than sarcopenia are risk factors for hospital mortality in critical illness. *J. Crit. Care* 56, 31–36 (2020).
7. Gonzalez, M. C., Barbosa-Silva, T. G. & Heymsfield, S. B. Bioelectrical impedance analysis in the assessment of sarcopenia. *J. Am. Med. Dir. Assoc.* 14(8), 531–532 (2013).
8. Yoshimura, Y. et al. Interventions for treating sarcopenia: A systematic review and meta-analysis of randomized controlled studies. *J. Am. Med. Dir. Assoc.* 18(6), 553 e1–553 e17 (2017).
9. Curcio, F. et al. Sarcopenia and heart failure. *Nutrients* 12(1), 211 (2020).
10. Ogawa, S., Yakabe, M. & Akishita, M. Age-related sarcopenia and its pathophysiological bases. *Inflamm. Regen.* 36, 17 (2016).
11. Qaisar, R. et al. Circulating biomarkers of accelerated sarcopenia in respiratory diseases. *Biology (Basel)* 9(10), 322 (2020).
12. Qaisar, R., Karim, A. & Muhammad, T. Circulating biomarkers of handgrip strength and lung function in chronic obstructive pulmonary disease. *Int. J. Chron. Obstuct. Pulmon. Dis.* 15, 311–321 (2020).
13. Phu, S. et al. The diagnostic value of the Short Physical Performance Battery for sarcopenia. *BMC Geriatr.* 20(1), 242 (2020).
14. Malmstrom, T. K. & Morley, J. E. SARC-F: A simple questionnaire to rapidly diagnose sarcopenia. *Sci. Rep.* 11, 2266–2273 (2017).
15. Fragala, M. S. et al. Circulating irisin levels as a predictive biomarker for sarcopenia: A cross-sectional community-based study. *Sci. Rep.* 11, 2944–2952 (2021).
16. Qaisar, R., Karim, A. & Muhammad, T. Plasma CAF22 levels as a useful predictor of muscle health in patients with chronic obstruc-
tive pulmonary disease. *Coron. Artery Dis.* 31, 173–181 (2020).
17. Jorgensen, L. H. et al. Muscle wasting associated co-morbidities, rather than sarcopenia are risk factors for hospital mortality in critical illness. *J. Crit. Care* 56, 31–36 (2020).
18. Berry, S. D. et al. Biochemical markers of muscle damage and high serum concentration of creatine kinase in patients on statin therapy. *Biomark. Med.* 13(8), 619–626 (2019).
19. Meng, S. J. & Yu, L. J. Oxidative stress, molecular inflammation and sarcopenia. *Int. J. Mol. Sci.* 11(4), 1509–1526 (2010).
20. Nogueira, A. A. et al. Biochemical markers of muscle damage and high serum concentration of creatine kinase in patients on statin therapy. *Biomark. Med.* 13(8), 619–626 (2019).
21. Sunanataraj, K. et al. Neuron specific reduction in CuZnSOD is not sufficient to initiate a full sarcopenia phenotype. *Redox Biol.* 5, 140–148 (2015).
22. Berry, S. D. et al. Procollagen type III N-terminal peptide (P3NP) and lean mass: A cross-sectional study. *J. Frailty Aging* 2(3), 129–134 (2013).
23. Bhasin, S. et al. N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone. *J. Endocrinol. Metab.* 94(11), 4224–4233 (2009).
24. Fragala, M. S. et al. Biomarkers of muscle quality: N-terminal propeptide of type III procollagen and C-terminal agrin fragment responses to resistance exercise training in older adults. *J. Cachexia Sarcopenia Muscle* 5(2), 139–148 (2014).
25. Petersson, S. J. et al. SPARC is up-regulated during skeletal muscle regeneration and inhibits myoblast differentiation. *Histol. Histopathol.* 28(11), 1451–1460 (2013).
26. Jorgensen, L. H. et al. Secreted protein acidic and rich in cysteine (SPARC) in human skeletal muscle. *J. Histochem. Cytochem.* 57(1), 29–39 (2009).
27. Kwak, J. Y. et al. Prediction of sarcopenia using a combination of multiple serum biomarkers. *Sci. Rep.* 8(1), 8574 (2018).
28. Reza, M. et al. Irisin is a pro-myogenic factor that induces skeletal muscle hypertrophy and rescues denervation-induced atrophy. *Nat. Commun.* 8(1), 1104 (2017).
29. Huh, J. Y. et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. *Metabolism* 61(12), 1725–1738 (2012).
30. Shan, T. et al. Myostatin knockout drives browning of white adipose tissue through activating the AMPK-PGC1alpha-Fndc5 pathway in muscle. *FASEB J.* 27(5), 1981–1989 (2013).
31. Chang, J. S. et al. Circulating irisin levels as a predictive biomarker for sarcopenia: A cross-sectional community-based study. *Geriatr. Gerontol. Int.* 17(11), 2266–2273 (2017).
32. Kubo, H. et al. Exercise ameliorates emphysema of cigarette smoke-induced COPD in mice through the exercise-irisin-Nrf2 axis. Int. J. Chron. Obstruct. Pulmon. Dis. 14, 2507–2516 (2019).
33. Shearer, J. et al. Partial gene deletion of heart-type fatty acid-binding protein limits the severity of dietary-induced insulin resistance. Diabetes 54(11), 3133–3139 (2005).
34. Lee, S. M. et al. FABP3-mediated membrane lipid saturation alters fluidity and induces ER stress in skeletal muscle with aging. Nat. Commun. 11(1), 5661 (2020).
35. Barreiro, E. et al. Endoplasmic reticulum stress and unfolded protein response profile in quadriceps of sarcopenic patients with respiratory diseases. J. Cell Physiol. 234(7), 11315–11329 (2019).
36. Hong, J. et al. The role of endoplasmic reticulum stress in cardiovascular disease and exercise. Int. J. Vasc. Med. 2017, 2049217 (2017).
37. Reimann, J. et al. Macrophage migration inhibitory factor in normal human skeletal muscle and inflammatory myopathies. J. Neuropathol. Exp. Neurol. 69(6), 654–662 (2010).
38. Mirza, S. et al. COPD guidelines: A review of the 2018 GOLD report. Mayo Clin. Proc. 93(10), 1488–1502 (2018).
39. C. N. C. F. C Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 59 Suppl 1, 1–232 (2004).
40. Scherbakov, N. et al. Evaluation of C-terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation. J. Cachexia Sarcopenia Muscle 7(1), 60–67 (2016).
41. Steinbeck, L. et al. Detection of muscle wasting in patients with chronic heart failure using C-terminal agrin fragment: Results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Eur. J. Heart Fail. 17(12), 1283–1293 (2015).
42. Seymour, J. M. et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur. Respir. J. 36(1), 81–88 (2010).
43. Sobestiansky, S., Michaelsson, K. & Cederholm, T. Sarcopenia prevalence and associations with mortality and hospitalisation by various sarcopenia definitions in 85–89 year old community-dwelling men: A report from the ULSAM study. BMC Geriatr. 19(1), 318 (2019).
44. World Medical, A. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 310(20), 2191–2194 (2013).
45. Landi, F. et al. HDL-cholesterol and physical performance: Results from the ageing and longevity study in the sirente geographic area (ilSIRENTE Study). Age Ageing 46(5), 514–520 (2007).
46. Alamdari, N. et al. Loss of muscle strength during sepsis is in part regulated by glucocorticoids and is associated with reduced muscle fiber stiffness. Am. J. Physiol. Regul. Integr. Comp. Physiol. 303(10), R1090–R1099 (2012).
47. Culver, B. H. et al. Recommendations for a standardized pulmonary function report. An Official American Thoracic Society technical statement. Am. J. Respir. Crit. Care Med. 190(11), 1463–1472 (2017).

Acknowledgements
This work was supported by grants from the University of Sharjah to Rizwan Qaisar (Competitive Grant # 1901090157, Target Grant # 1901090168). We are thankful to Waleed Yousaf, Faisal Nadeem & Ahmad Hassan Nadeem for helping with data analysis.

Author contributions
R.Q. designed experiments. A.K., T.M., I.S. & J.K. provided experimental materials and technical support. R.Q. & A.K. performed data acquisition and statistical analysis. R.Q. wrote the manuscript. All authors have read and approved the final draft.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-87974-6.

Correspondence and requests for materials should be addressed to R.Q.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021